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LIST OF ACRONYMS AND DEFINITIONS 
 
Adherence:  Adherence to long term therapy is defined as the extent to which a person’s behaviour 
(taking medication, following a diet and/or executing lifestyle changes) corresponds with the agreed 
upon recommendations from a health care provider. 
AIDS:  Acquired Immune Deficiency Syndrome 
ARV:  Antiretroviral  
ART:  Antiretroviral Therapy 
FDC:  Fixed dose combination  
HAST:  HIV/AIDS, STI & TB 
HIV:  Human Immunodeficiency Virus 
KZN:  KwaZulu-Natal 
Rural area:  Any area that is not classified as urban.  Rural areas are subdivided into tribal areas and 
commercial farms. 
Deep-rural area: an area that is not classified as urban and usually under jurisdiction of tribal 
authorities, headed by chiefs, while sub-chiefs are direct principals of villages.  These areas are 
generally with limited general basic services such as water and sanitation facilities.   
Semi-urban area:  an area between a rural and an urban area, or partially urban, that which is not 
wholly characteristic of an urban area.   
STI:  Sexually transmitted infections 
TB:  Tuberculosis 











The roll-out of antiretroviral (ARV) treatment in public health facilities was initiated in 2004 in the 
KwaZulu-Natal province.  The roll-out made ARV treatment available and accessible to the vast 
majority of the population which previously could not afford treatment due to their low socio-
economic status.  Adherence levels need to be monitored timeously in order to ensure that patients are 
adherent to their treatment.  Treatment outcomes are affected by the level of adherence to treatment. 
Adherence to treatment is essential in providing a sustainable and effective antiretroviral rollout 
campaign. The ARV roll-out has been initiated in all areas of society in South Africa, and it is a 
known fact that there are certain factors that affect the level of adherence.  It is therefore critical to 
measure the level of adherence to treatment by patients and to assess the factors that affect adherence.  
Few studies were done to determine whether geographical location of the patients and their clinics had 
an effect on adherence.  This study was therefore undertaken with the following aims and objectives 
Aim and Objectives 
The specific objective of the study was to describe the demographics of the patients attending ART 
clinics in rural, deep rural and semi-urban areas of Ugu District in KwaZulu-Natal, to measure the 
level of adherence to ARV therapy, and to determine the factors that affect adherence to the therapy in 
these areas. 
Method  
A retrospective chart analysis of 1020 Human Immunodeficiency Virus (HIV) infected patients (18-
60 years of age) who reside in Ugu District within the catchment population of the facility ,   
registered on the ART programme in the facility and  have been receiving ART from the facility for at 
least 2 years were selected to be in the study.  The following research sites were chosen:   1 rural 
hospital, 1 deep-rural clinic and 1 semi-urban community health centre was chosen.  Records of the 
patients from January 2011 to December 2014 were examined in order to select the patients. A closed-
ended, coded questionnaire was administered to all patients in the study & was used to record the 
demographics, level of adherence and factors affecting adherence.  After obtaining their consent the 
questionnaires were administered.  The data was captured and analysed using SPSS version 23 
software. 
Results 
Of the 1020 patients, there were 623 females (61%), with most patients between 18-35 years (56.9%).  
Almost 70% of the patients were African, with 57.5% single and 75.9% having less than 3 
dependants.  Forty nine percent of the patients had secondary level education, whilst 61.2% of them 
ix 
 
were unemployed.  More than 62% of the patients use public transport to get to these facilities.  Over 
two thirds of the patients (67%) were on the Fixed Dose Combination treatment, with 70% of the 
patients already on treatment for 2-4 years, and 30% on treatment for more than 4 years.  More than 
half of the patients (51.7%) had missed between 2-4 appointments to collect their medication from 
health facilities in the previous 6 months.  Although 80.9% of the respondents indicated that they 
understood the importance of adherence (p=0.008) an overall 58.5% were actually adherent to 
treatment, with the majority coming from the deep rural area (p=0.001). 
A number of factors affected the adherence to treatment for patients in the 3 areas, both positively and 
negatively, the first being their transport to the facility.  A larger percentage of patients in the deep-
rural (12.4%) area reported taking 2-3 hours (p=0.000) to arrive at these facilities due to transport 
problems.   Over ten percent in the deep-rural area reported having travelled 15-20km (p=0.00).The 
second reason related to weather, where a much larger proportion of patients (73.8%) in the deep-rural 
area associated the weather with their ability to reach the health facilities to collect their medication. 
Other reasons included waiting time, where a great majority of patients from the semi-urban area 
(87.1%) reported to having waited longer than 2 hours to be attended to.  With respect to stock 
outages 15.4% of patients in all 3 areas were affected by stock outages.   Over 40% (42.8%) of the 
overall patients were affected by family deaths.  They could not attend their clinics resulting from 
having to make arrangements for the burial of their loved ones. This significantly affected patients in 
the deep rural area (54.4%). Close to 25% of patients were the only caregivers at home, thereby 
sometimes being unable to collect their medication from the facilities due to having small dependants 
who cannot be left unattended at home. A greater majority (75.9%) of patients admitted to not 
collecting their medication from health facilities due to having sufficient treatment at home, with the 
smaller proportion (66.8%) being in the rural area (p=0.00).Forty two percent of patients related being 
depressed as one of the reasons for not taking their medication, with the larger proportion (49.4%) 
being in the semi-urban area (p=0.004). Over half of all patients (50.7%) used traditional medicines 
with the reported use of alcohol higher in the deep-rural area (93.5%) than in the other areas.    Just 
over a quarter of the participants were involved in substance abuse.  A larger proportion (62.4%) of 
patients who did not disclose their status were in the semi-urban area, compared to the other 2 areas 
(p=0.008), with 69.8% of patients indicating a fear of loss of social grant if adherent to treatment.  
This fear was much greater in the deep-rural area (88.5%) than in the other areas (p=0.000).  A larger 
proportion of patients (30.9%) in the semi-urban area reported that they were not granted leave from 
work to collect their medication.   Regimen changes affected adherence in 32% of patients while 
compliance to treatment for 67.9% of the patients was affected by side-effects.   The association 
between mistrust of the new single tablet and adherence was statistically significant (p=0.023).  A 
lower proportion of urban patients (35.6%) showed mistrust compared to the other areas, and  18.8% 
of patients taking single agents missed one of the two daily doses, with most (25.9%) of the patients 
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who missed the dose being from the semi-urban area.  Over 51% of patients did not see the need of 
taking their medication due to feeling better.  This generally affected all 3 areas.  
Ninety two percent of patients in the deep-rural area indicated that they felt safe in the facility 
compared to the other areas.  Just over half of the patients attending the semi-urban area clinic liked 
their facility, compared to 91.8% of the deep-rural area and 95.9% of the rural area patients.  Staff 
attitude affected adherence, where71.2% in the deep-rural area felt that the staff attitude was good 
compared to the perception of patients in the other two areas (p=0.00).  A larger proportion (87%) of 
the patients in the semi-urban area reported food frequently being available thus enabling them to take 
their medication, whilst 46.5% of these patients felt that reminder methods were not effective 
compared to 57.4% (rural) and 58.5% (deep-rural). 
Conclusion 
The adherence levels of patients in rural, deep-rural and semi-urban areas are affected by various 
factors.  The area of residence had statistical significance in some of the factors that affected 














1.  Introduction  
1.1 Background and Literature Review 
South Africa has the biggest and most high profile HIV epidemic in the world, with an estimated 7.1 
million people living with HIV in 2016. One third of all new infections in the region in 2016 were in 
one country: South Africa. 
1
 In the same year, there were 270,000 new infections while 110,000 South 
Africans died from AIDS-related illnesses.
1
 
South Africa has the largest antiretroviral treatment (ART) program globally and these efforts have 
been largely financed from its own domestic resources. The country now invests more than R22 
billion annually to run its HIV and AIDS programmes.
2
 However, HIV prevalence remains high 
(18.9%) among the general population, although it varies markedly between regions.
1
   For example, 




Although more potent ARV regimens can allow for effective viral suppression at moderate levels of 
adherence, 
4, 5, 6
 partial or non-adherence can lead to the development of resistant strains of the virus.  
Some of the common barriers identified and cited include fear of disclosure, alcohol use, traditional 
medicine use, feeling better on treatment, inadequate knowledge about the disease and ARVs, stigma, 
transport costs, 
7, 8, 9
 lack of social support (financial and emotional), discrimination, depression and 
hopelessness, not being able to disclose their HIV status and a lack of food, 
9
 service related factors, 
8
 
patients beliefs and behaviours, 
8
 pill burden and drug side effects.
8
  
Patients’ behaviour is the critical link between a prescribed regimen and treatment outcomes.  The 
most effective regimen will fail if the patient does not take the medication as prescribed or refuses to 




Adherence to long term therapy, according to WHO, 
10
 is defined as a person’s behaviour (taking 
medication, following a diet and/or executing lifestyle changes) corresponding with the agreed upon 
recommendations from a health care provider.   
Poor adherence can lead to clinical, immunological and virological failure with the latter resulting into 
the spread of drug resistant forms of the virus which is of public health concern.  It can also lead to 




Since the gold standard approach for assessing ART adherence has not been established many 
researchers use patient self-reporting because of its low cost and simplicity, although this measure has 
2 
 
led to underestimation of non-adherence. Pharmacy adherence measures (PAM) are also relatively 
simple to administer and have provided more clinically relevant results compared to self-reports.
13
 
Adherence is a dynamic process that changes over time and predictors of non-adherence vary 




There is a need to establish whether the desired levels of adherence can be achieved and maintained in 
different settings (rural, deep rural and semi-urban) where patients living with HIV/AIDS live, collect 
and administer their ARV treatment; and what the determinants of adherence to ARV treatment in 
such settings are. 
This study therefore focussed on measuring adherence levels of patients taking ARV treatment in 
rural, deep rural and semi-urban areas and compared the different factors that affect adherence in 
these different areas of society thereby establishing whether the geographical location of the facilities 
has an impact on the level of adherence to treatment. 
1.2 Core Research Problem and Clinical Significance 
With the advent of ART, HIV/AIDS has become a chronic disease, therefore adherence to HIV 
medication is an extremely complicated process that includes drugs to provide the conditions for 
effective drug therapy.  Some regimens require several doses of medication per day together with 
various requirements or restrictions on food intake.
10, 11
 
Good adherence is crucial for maximum clinical benefit from antiretroviral therapy.  Therefore 
despite increasing access to antiretroviral drugs, the long-term success of treatment programs in 
resource limited settings requires establishing the optimum levels of adherence.  Factors that make 
patients on ART fail to obtain good adherence have to be determined and addressed. 
Therefore, the statement of the research problem for this study is: 
What are the factors that affect adherence to antiretroviral therapy in HIV positive patients treated in 
rural, deep rural and semi-urban areas of Ugu District in KwaZulu-Natal, and how adherent to ARV 
therapy are patients attending ARV clinics in these 3 different settings in Ugu District in KwaZulu-
Natal?  
The hypothesis is, therefore, that HIV positive patients visiting rural, deep rural and semi-urban ARV 
clinics in Ugu District are adherent to their antiretroviral therapy.  
The current public health arena is grappling with issues of treatment adherence for chronic diseases.  
Knowledge gained from this study about factors in the population associated with adherence and non-
adherence to antiretroviral therapy by HIV positive patients will help in making recommendations 
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regarding the development of appropriate health education strategies to empower patients about the 
importance of adherence to ART. 
The information will be used to develop guidelines and education materials that can be used in 
adherence counselling before patients are started on ART and during the follow-up periods after 
starting.   
The findings will also contribute to the review of the HIV/AIDS treatment protocols and policies, 
related in-service education for medical personnel and review of health education programs for HIV 
positive patients so as to improve the clinical management of HIV/AIDS.   
A research poster based on the results can also be developed for presentation in seminars, workshops 
and related conferences to empower health professionals on issues of adherence to ART. 
1.2 Aim of the study 
The study aimed at conducting a survey in order to determine the factors that affect adherence to 
antiretroviral therapy in HIV positive patients treated in rural, deep rural and semi-urban areas of 
Kwazulu-Natal, and find out how adherent to ARV therapy are patients attending ARV clinics in 
these 3 different settings in KwaZulu-Natal. 
1.3 Specific Objectives Of The Study 
The following were the specific objectives of the study: 
- To describe the demographics of the patients visiting the ARV clinics.  
- To evaluate the level of understanding of patients with regards to the meaning and importance 
of adherence. 
- To determine the level of adherence of patients in the 3 different geographical locations. 




The research methodology outlines the logical process of the research and what processes and 
procedures are followed to answer the research question and achieve the research objectives.
15
   
1.4.1 Research Context 
According to Polit & Beck, 
16
 a research context is defined as a specific place where data collection 
occurs.  Three (rural, deep-rural and semi-urban) health facilities within Ugu District in KwaZulu-
Natal will be selected as the research context.  Facilities that were chosen were facilities that provide 
comprehensive HIV/AIDS services. 
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Ugu Health District is found in the lower South Coast of the Province of KZN. The neighbouring 
Districts are Ethekwini and Sisonke. The estimated population is 760 285. The district provides health 
service to the population using the Primary Health Care approach through the District Health System 
and this is done at all levels of care.   
This district comprises of six local municipalities namely: Vulamehlo, Umdoni, Umzumbe, Hibiscus, 
Izinqoleni and Umzwabantu.  There are also three Emergency Medical Rescue Service bases and 
three Medico-Legal Mortuaries 
There are three District Hospitals, one Regional Hospital, one Specialised Hospital, two Community 
Health Centres; 56 fixed clinics (including three Gateway clinics), and 15 Mobile Clinics with 216 
visiting points in 84 wards. There are ten local authority clinics in the District. 
1.4.2 Study Population 
According to Polit & Beck, 
16
 the study population is defined as the entire aggregation of cases in 
which the researcher is interested.  The target population however, is defined as the total group of 
subjects about whom a researcher is interested and from whom results could reasonably be generated. 
For this study, the target population was all adults (i.e. 18 to 60 years of age) male and female HIV 
positive patients on ART for more than two years in Ugu District. 
Accessible population, according to Polit & Beck, 
16
 is the aggregate of cases that conform to 
designated criteria and are available as subjects for a particular study.  Burns & Grove 
17
 define it as 
the portion of the target population to which the researcher has reasonable access. 
For this study, the accessible population was all adult male and female HIV positive patients 
accessing ART from the chosen rural, deep-rural & semi-urban health facilities in Ugu District in 
KZN. 
      1.4.3 Inclusion Criteria 
Eligibility criteria, according to Polit & Beck,
16
 is the criteria that designates the specific attributes of 
the target population by which people are selected for inclusion in a study. 
The following inclusion criteria was used to identify the study population 
  Adult male and female (18-60 years of age). 
 Registered as an ARV patient at the chosen facilities. 
 Receiving ART from the chosen facilities  
 Been on ART in the chosen facilities for at least two years. 




1.4.4 Exclusion criteria 
 All patients <18 years of age. 
 All patients who had not completed two years being on ARV therapy. 
 All patients who do not reside in Ugu District.  
 
1.4.5 Sample and sampling technique 
A sample is a subset of the study population that is selected for a particular study and the members of 
the sample are the respondents.  Sampling is defined by Burns & Grove 
17
 as the process for selecting 
a group of people, events, behaviour or other elements with which to conduct a study. 
A sampling technique is the method used to select a sample from the study population.
16
 At the time 
of the study, a total of 47 643 patients were on ARV treatment from the 63 health facilities in Ugu 
District.  Three health facilities were selected for this study i.e. one rural (Murchison Hospital), one 
deep-rural (Elim Clinic) and one semi-urban (Gamalakhe CHC) facility.  These 3 facilities were 
chosen based on having the highest volume of HIV patients collecting treatment within the 3 different 
geographical areas at the time of the study.  A total of 9786 patients collected ARV treatment in the 
rural (n= 2982), deep-rural (n=3284) and semi-urban (n=3520) areas.  A retrospective chart analysis 
was done of HIV positive patients who visited the health facilities from January 2011 to December 
2014.  The charts were reviewed on Mondays, Wednesdays and Fridays during ARV clinic days at the 
3 sites.  The patients who refused to be part of the study were excluded. Charts with missing records 
were also excluded from the study. 
A total 1630 patients met the inclusion criteria (450 in the rural area, 560 in the deep-rural area and 
620 in the semi-urban area).  These were patients between 18-60 years of age, were receiving ART 
from the selected facilities in Ugu District and had been on treatment for 2 years or longer.  
These results were submitted to the Statistician for input and validation of sample size.  The 
Statistician suggested that a total sample size of 1020 patients be randomly chosen with 340 patients 
chosen from each area.   
The random sampling approach was used to select the 1020 patients from the 1630 that met the 
inclusion criteria in order to obtain a representative sample.  The first, and thereafter every sixth 
patient was chosen to randomly select a total of 340 respondents from each area.           
1.4.6 Data Collection 
Some studies define adherence using a categorical definition as “no missed or reduced doses” during a 
given time period and other set the criterion for adherence as meeting minimum level of drug 
consumption at 95% or more, measured using pill counts.   
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With reference to this study, adherence was measured as self-reported adherence to ART by the HIV 
positive patient that was measured against the available counted pills at the time of the following 
monthly visit to the health facility, with the minimum acceptable drug consumption of 95% i.e. 
Pharmacy refill method was used to measure adherence in this study. Adherence rates from pharmacy 
refill records are determined by comparing the actual with expected refill dates or by identifying 




According to Polit & Beck, 
16
 structured data collection involves a fixed set of questions to be 
answered in a specified sequence and with pre-designated response options.  
 The use of a questionnaire is associated with advantages such as less cost, respondent anonymity, 
absence of interviewer bias, easy to administer and data yielded is easy to analyse.  However, it has 
disadvantages including low response rates, the questions tend to have less depth especially if they are 
closed-ended questions and the respondent is unable to elaborate on the response or ask for 
clarification of the questions.
17
 
The study used a structured data collection approach in the form of a questionnaire with closed-ended 
questions.  In this study, a structured questionnaire was utilised so as to focus the research process and 
also be able to quantify the results of the study phenomenon. 
Consent was obtained from the respondents for the administration of the questionnaire.  The 
questionnaire was then administered to all the 1020 respondents in order to determine the level of 
understanding of the importance of adherence, the level of adherence to treatment and the factors that 
affected adherence in the 3 geographical areas.  A separate, private room was used to complete the 
questionnaire. 
Variables recorded for each HIV positive patient meeting the set criteria were as follows: 
a.  Demographics 
(i)  Age  
(ii) Gender 
(iii) Marital status 
(iv) Race 
(v) Level of education 
(vi) Number of dependants 
(vii) Occupation 
(viii) Treatment regimen 
(ix) Mode of transport 
(x) Duration on ARV Therapy 
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(xi) Period medication not taken 
b.  Measure of adherence:  adherence / non-adherence 
c.  Factors affecting adherence 
(i) Understanding the importance of adherence to treatment 
(ii) Facility issues 
- Transport to the facility 
- Distance to the facility 
- Safety of the facility 
- Facility preference 
- Staff attitudes 
- Waiting time 
- Stock outages 
(iii) Social issues 
- Family death 
- No other caregiver at home 
- Sufficient stock 
- Depression resulting from taking the medication 
- Food availability 
- Reminder methods not effective 
- Traditional medicine use 
- Alcohol use 
- Substance abuse 
- Non-disclosure of status 
- Fear of Social Grant loss 
(iv) Work issues 
- No leave granted at work 
(v) Weather 
(vi) Feeling better 
(vii) Time of taking medication 
(viii) Quantity of tablets taken (pill burden) 
(ix) Treatment regimen changes 
(x) Side effects 
(xi) Missed doses 





Validity is an important concept and is of concern throughout the research process.  It is important to 
the researcher during the research process and to those who read the study report as they provide a 
basis for making decisions as they consider using the findings in their practice. 
According to Polit & Beck,
16
 validity is defined as the degree to which an instrument measures what it 
is supposed to measure.   
Validity varies from one sample to another and from one situation to another; therefore, validity 
testing actually validates the use of an instrument for a specific group or purpose rather than the 
instrument itself. 
In this study, the degree of face, content, internal and external validity of the instrument for the 
intended purpose and the context where the study is conducted were determined. 
In this study, face validity was ensured by carefully selecting the items to be included in the 
questionnaire.  These items reflect the concept of adherence to ART and the factors that affect it in 
HIV positive patients.  It was also established by consulting the medical colleagues of the researcher 
and the study supervisor to make inputs. 
To enhance content validity, the questionnaire was presented for review to the statistician and study 
supervisor to make inputs.  This helped in refining questions for better meaning, clarity and 
conceptualisation. 
To enhance internal and external validity, it was ensured that the accessible population is as much as 
possible similar in characteristics to the target population. 
1.4.8 Data Analysis  
According to Burns & Grove, 
17
 data analysis is defined as a process that is conducted to reduce, 
organise and give meaning to the collected data. 
Quantitative data management and analysis was done using SPSS version 23 software (Chicago, 
Illions, USA) program with the assistance of the statistician.   
The variables of the respondents such as age, gender, marital status, source of income, educational 
level, HIV status disclosure to spouse/partner, alcohol use and adherence level will be used in the 
analysis of data to describe and make inference to the sample population. 
Chi-Square test was used to assess the variables.  A p-value of < 0.05 was considered statistically 
significant. 
  1.5 Dissertation structure 
Chapter 1:  
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- Background and Literature Review 
- Core research  problem and clinical significance of the study 
- Formulation of aims and specific objectives of the study 
- Research Methodology 
Chapter 2: -   Presentation of manuscript entitled “Does the geographical location of HIV positive 
patients attending antiretroviral clinics in selected rural, deep-rural and semi-urban areas of Ugu 
District in KwaZulu-Natal affect adherence?” submitted to the South African Family Practice Journal. 
Article is presently under review. 
Chapter 3:       -    Discussion of findings 
- Limitations of the study 
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Adherence to antiretroviral (ARV) treatment is essential in order to improve treatment outcomes.  Many factors 
influence adherence to ARV treatment.  However, not many studies have surveyed the impact of geographical 
location of patients as a factor contributing to adherence.  This study was therefore undertaken to assess the 
level of adherence, the impact of the geographical location of patients on adherence levels and to confirm other 
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Adherence to antiretroviral (ARV) treatment is essential in order to improve treatment outcomes.  Many factors 
influence adherence to ARV treatment.  However, not many studies have surveyed the impact of geographical 
location of patients as a factor contributing to adherence.  This study was therefore undertaken to assess the 
impact of the geographical location of patients on adherence levels and to confirm other factors that affect 
adherence in these areas. 
Methods  
Retrospective chart analysis of 1020 Human Immunodeficiency Virus (HIV) infected patients (age >18-60 
years; treatment period≥ 2 years) in one rural, one deep-rural and one semi-urban health facility were analysed 
to determine the level of adherence.  The 1020 patients were chosen by selecting the first, and thereafter every 
sixth patient.  Charts with missing records were excluded from the study.  A questionnaire was then 
administered to these patients to confirm adherence levels and determine factors that affected adherence. 
Results 
Majority (61%) of the respondents were females.  Though 80.9% of all respondents understood the importance 
of adherence only 58.5% were adherent to treatment, with 89.4% of these adherent patients residing in the deep 
rural area. Factors affecting adherence were cited by respondents from certain geographical areas more than 
others, such as transport, facility preference, staff attitude, waiting time, food availability, alcohol use and social 
grant. There were also common factors affecting adherence in these respondents across the 3 geographical areas 
such as distance, stock, depression and mistrust of new single [Fixed Dose Combination] tablet.  
Conclusion 
Factors, due to the geographical location of the respondents, did affect the adherence whilst there were many 























South Africa has the highest number of HIV infected people worldwide with an estimated 5.6 million people 
living with HIV. 
1
 The challenge has shifted from access to adherence with increased access to antiretroviral 
therapy. 
2, 3
 Although more potent ARV regimens can allow for effective viral suppression at moderate levels of 
adherence,
4, 5, 6
 non or partial adherence can lead to the development of resistant strains of the virus.   
Some of the common barriers identified and cited include fear of disclosure, alcohol use, traditional medicine 
use, feeling better on treatment, inadequate knowledge about the disease and ARVs, stigma, transport costs, 
7, 8, 9
 
lack of social support (financial and emotional), discrimination, depression and hopelessness, not being able to 
disclose their HIV status and a lack of food, 
9
 service related factors, 
8
 patients beliefs and behaviours,
8
 pill 
burden and  drug side effects.
8
 Patients’ behaviour is the critical link between a prescribed regimen and 
treatment outcomes.  The most effective regimen will fail if the patient does not take the medication as 
prescribed or refuses to take it at all.  Consequently all things being equal, the most important factors 
influencing adherence are patient-related.
2, 10
 
Adherence to long term therapy, according to WHO, 
2
 is defined as a person’s behaviour (taking medication, 
following a diet and/or executing lifestyle changes) coinciding with the agreed upon recommendations from a 
health care provider.  Poor adherence can lead to clinical, immunological and virological failure with the latter 
resulting into the spread of drug resistant forms of the virus which is of public health concern.  It can also lead to 




There is a need to establish whether the desired levels of adherence can be achieved and maintained in different 
settings (rural, deep rural and semi-urban) where patients living with HIV/AIDS live, collect and administer 
their ARV treatment; and what the determinants of adherence to ARV treatment in such settings are.  This study 
therefore focussed on measuring adherence levels of patients taking ARV treatment in rural, deep rural and 
semi-urban areas and compared the different factors that affect adherence in these different areas of society 
thereby establishing whether the geographical location of the facilities has an impact on the level of adherence 
to treatment. 
Methods 
A retrospective chart analysis of 1020 Human Immunodeficiency Virus (HIV) infected patients (18-60 years of 
age) who reside in Ugu District within the catchment population of the facility ,   registered on the ART 
programme in the facility and  have been receiving ART from the facility for at least 2 years were selected to be 
in the study.  Research sites chosen were 1 rural hospital, 1 deep rural clinic and 1 semi urban community health 
centre.  Records of the patients from January 2011 to December 2014 were examined in order to select the 
patients. The first, and thereafter every sixth patient was chosen to randomly select patients.   Patients who 
refused to be part of the study were excluded.  Charts with missing records were also excluded from the study.  
A closed-ended, coded questionnaire was administered to all patients in the study & was used to record the 
demographics, level of adherence and factors affecting adherence.  After obtaining patient consent the 
questionnaires were administered.  Most studies set the criterion for adherence as meeting minimum level of 
drug consumption at 95% or more, measured using pill counts.  With reference to this study, adherence was 
measured as self-reported adherence to ART by the HIV positive patient that was measured against the available 
counted pills at the time of the following monthly visit to the health facility, with the minimum acceptable drug 
consumption of 95% i.e. Pharmacy refill method was used to measure adherence in this study. Adherence rates 
from pharmacy refill records are determined by comparing the actual with expected refill dates or by identifying 
“medication gaps”, defined as periods during which the patient’s supply of medication is assumed to have been 
exhausted.
12
   
Using this method to record and measure adherence is common among settings in which medication is provided 
and financed in a single location especially in a closed pharmacy system provided that the refills are measured at 
several points in time.   
The data was captured and analysed using SPSS version 23 software. A p-value of < 0.05 was considered 
statistically significant.  Gatekeepers permission was given by the KwaZulu Natal Department of Health 
Research and Development Committee with the study  given full ethical approval from the Biomedical Research 








The socio-demographic profile of the respondents is shown in Table I below.   
Table I:  Socio-demographic profile of the respondents (n=1020) 
 
 
Overall    
n (%) 
Rural        
n (%)* 
Deep Rural        
n (%)* 








































709 (69.5) 244 (71.8) 
 
235 (69.1) 230 (67.6) 
Asian 
 
157 (15.4) 48 (14.1) 52 (15.3) 57 (16.8) 
White 
 
81 (7.9) 25 (7.4) 27 (7.9) 29 (8.5) 
Coloured 73 (7.2) 23 (6.8) 26 (7.6) 24 (7.1) 





202 (59.4) 196 (57.6) 189 (55.6) 
Married 433 (42.5) 138 (40.6) 144 (42.4) 151 (44.4) 
No. of dependants  
0-3 
 
774 (75.9) 254 (74.4) 235 (69) 285 (83.8) 
≥ 3 
 
246 (24.1) 86 (25.6) 105 (31) 55 (16.2) 
Level of education  
No education 
 
50 (4.9) 15 (4.4) 25 (7.4) 10 (2.9) 
Primary level 
 
316 (31.0) 91 (26.8) 167 (49.1) 58 (17.1) 
Secondary level 
 
500 (49.0) 173 (50.9) 99 (29.1) 228 (67.1) 




624 (61.2) 204 (60) 190 (55.9) 230 (67.6) 
Employed 396 (38.8) 136 (40) 150 (44.1) 110 (32.4) 
















112  (11.0) 
 
35 (10.3) 38 (11.2) 39 (11.5) 
Private vehicle 
 
135 (13.2) 43 (12.6) 44 (12.9) 48 (14.1) 
*%= total number of affected respondents/ total number of respondents in that area x100 
Majority of respondents were females and in the 18-35 age group. Of this age group over 78% were from the 
deep rural area.  Over 60% were unemployed.  Forty nine percent of the patients had secondary level education.  
More than 62% of the patients use public transport to get to these facilities.   
ARV Treatment 
Table II:  ARV Treatment (n=1020) 
 
 
Overall    
n (%) 
Rural        
n (%)* 
Deep Rural        
n (%)* 
Semi Urban        
n (%)* 







90 (26.5) 92 (27.1) 93 (27.4) 




231 (67.9) 227 (66.8) 225 (66.2) 
Regimen 2 62 (6) 
 
19 (5.6) 21 (6.2) 22 (6.1) 
Period on treatment  
 
2-4 years 711 (70) 
 
241 (70.9) 266 (78.2) 204 (60) 
>4 years 308 (30) 
 
98 (28.9) 74 (21.8) 136 (40) 




180 (52.9) 237 (69.7) 110 (32.4) 
*%= total number of affected respondents/ total number of respondents in that area x100 
Over two thirds of the patients (67%) were on the Fixed Dose Combination treatment, with over 51.7% missing 
2-4 appointments, the majority coming from the deep rural area.  
Adherence 
Table III:  Measure of adherence and the understanding of the importance of adherence by the respondents 
(n=1020) 
 Overall         
n (%) 
Rural          
n (%)* 
Deep Rural      
n (%)* 
Semi Urban      
n (%)* 
P-value 
Adherent to treatment 597 (58.5) 





113 (33.2) p=0.001 
Understand the 
importance of adherence 
 
825 (80.9) 326 (95.9) 312 (91.8) 187  (55.0) p=0.008 
*%= total number of affected respondents/ total number of respondents in that area x100 
It can be seen from Table III that even though 80.9% of the respondents indicated that they understood the 
importance of adherence an overall 58.5% were actually adherent to treatment, with the majority coming from 
the deep rural area. 
Factors affecting adherence 
 The factors affecting adherence are listed in Table IV below. 





 Overall    
n (%) 
Rural        
n (%)* 
Deep Rural        
n (%)* 
Semi Urban        
n (%)* 
P-value 
Factors adversely affecting adherence 
 
Transport to 
facility (2-3 hours) 
95 (9.3) 38 (11.2) 42 (12.4) 
 
15 (4.4) p=0.000 
Distance to facility 
(15-20km) 
72 (7.1) 21 (6.2) 36 (10.6) 15 (4.4) p=0.000 
Weather 468 (45.9) 185 (54.4) 251 (73.8) 32 (9.4) p=0.000 
Waiting time 
(>2hours) 





Stock outages 157 (15.4) 49 (14.4) 53 (15.6) 55 (16.2) p=0.810 
Family death 437 (42.8) 147 (43.2) 185 (54.4) 105 (30.9) p=0.000 
No other caregiver 
at homer 
253 (24.8) 78 (31) 51 (15) 124 (36.5) p=0.000 
Sufficient stock at 
home 
774 (75.9) 227 (66.8) 271 (79.7) 276 (81.2) p=0.000 
Feeling depressed 433 (42.5) 126 (37.1) 139 (40.9) 168 (49.4) p=0.004 
Traditional 
medicine use 
517 (50.7) 175 (51.5) 169 (49.7) 173 (50.9) p=0.980 
Alcohol use 759 (74.4) 178 (52.4) 318 (93.5) 263 (77.4) p=0.000 
Substance abuse 259 (25.4) 85 (25) 83 (24.4) 91 (26.8) p=0.764 
Non-disclosure of 
status 







Social grant 712 (69.8) 264 (77.6) 301 (88.5) 147 (43.2) p=0.000 
No leave granted 
from work 
308 (30.2) 103(30.3) 100 (29.4) 105 (30.9) p=0.000 
Pill burden  
(>4 tablets) 
675 (66.1) 216 (63.5) 227 (66.8) 232 (68.2) p=0.514 
Regimen change 326 (32) 106 (31.2) 96 (28.2) 124 (36.5) p=0.066 
Side effects 693 (67.9) 235 (69.1) 230 (67.6) 228 (67.1) p=0.995 
Mistrust of new 
single tablet 
413 (40.5) 121 (35.6) 136 (40) 156 (45.9) p=0.023 
Missed doses 192 (18.8) 40 (11.8) 64 (18.8) 88 (25.9) p=0.000 
Time of taking 
medication 
134 (13.1) 46 (13.5) 25 (7.4) 63 (18.5) p=0.964 
Feeling better 523 (51.3) 179 (52.6) 162 (47.6) 182 (53.5) p=0.254 
Factors promoting adherence 
Facility safety 876 (85.9) 294 (86.5) 313 (92.1) 269 (79.1) p=0.000 
Facility preference 825 (80.9) 326 (95.9) 312 (91.8) 187 (55.0) p=0.000 
Staff attitude 610 (59.8) 207 (60.9) 242 (71.2) 161 (47.4) p=0.000 
Food availability 592 (58) 100 (29.4) 196 (57.6) 296 (87) p=0.000 
Reminder methods 552 (54.1) 195 (57.4) 199 (58.5) 
 
158 (46.5) p=0.002 
*%= total number of affected respondents/ total number of respondents in that area x100 




Factors promoting adherence 
Deep-rural Area Rural Area Semi-urban Area 
Clean and safe facility  Facility preference  Food availability  
Good staff attitude    
Use of reminder aids    
Factors adversely affecting adherence 
Deep-rural Area Rural Area Semi-urban Area 
Transport  Traditional medicine use  Waiting time  
Distance  Side Effects  Stock outages  
Weather   Having no other caregiver at home  
Family death  Having sufficient stock at home  
Alcohol use   Feeling depressed  
Fear of loss of social grant   Substance abuse  
  Non-disclosure of  HIV status  
  Not being granted leave from work 
  Pill burden  
  Regimen change  
  Mistrust of new single FDC tablet  
  Missing one of the two daily doses for 
patients not on FDC 
  Time of taking medication  
  Feeling better  
 
Discussion 
The majority of respondents being females, and the prevalence of HIV in the 18-35 age group is consistent with 
the 2012 survey which found that HIV prevalence amongst South African women was nearly twice as high as 
men, 
13
 and that rates of new infections among women aged 15-24 were more than four times greater than that 
of men of the same age.
14
 
With respect to their understanding, although 80.9% of the respondents indicated that they understood the 
importance of adherence, an overall 58.5% were actually adherent to treatment, with the majority (89.4%) 
coming from the deep rural area (p=0.001) compared to the rural (52.9%) and semi urban (33.2%) areas.  This 
raises concerns as all patients included in this study had been on treatment for more than 2 years and provision 
of HIV/AIDS education and counselling to the patients is continuously done at every encounter with the 
healthcare providers at the healthcare facilities. The practice of being adherent by these patients appears to be 
neglected even though they are knowledgeable about the importance. A further survey determining what they 
actually understand about adherence and its importance should be carried out to devise appropriate interventions 
to help the patients obtain optimal adherence to ART. 
In terms of the factors that affect adherence to ARV treatment, the time of travelling between home and the 
facilities was significantly associated with the area of residence (p=0.000).  A larger percentage of patients in 




20km at a cost. In a study done in Botswana 
15
 it was reported that the cost incurred through transport to visit 
ART clinics was a major obstacle that had a negative impact on optimal adherence to ART.  This concurs with 
results found in this study where distance travelled to health facilities impacts on the transport costs thus 
adversely affecting adherence due to the burden of paying for transport to ART sites.   
The weather was significantly associated with the level of adherence to treatment (p=0.000).  A much higher 
proportion of the deep-rural area patients (73.8%) associated the weather with their ability to collect medication 
from the health facility.  Rainy weather makes it difficult to travel to ART sites from the deep rural area as 
rivers that are crossed on foot are sometimes full.  Great discomfort is also caused by sunny weather for patients 
who walk to these facilities. 
In terms of relating waiting time and adherence, there was a significant association noted between waiting time 
and adherence (p=0.000).   A total of 635 (62.3%) patients waited in the queue for 2 hours and longer, with a 
significantly higher number of patients from the semi-urban (n=296; 87.1%) area reported having waiting times 
of greater than 3hours. A previous study found that patients who stayed in queues for a long time (4 hours or 
more) before being helped by service providers find it difficult to fulfil all appointments as they think about past 
experiences encountered at the health facility.
16
 
The death of a family member showed to have a statistical significance on level of adherence (p=0.000) and 
meeting their appointments.  A total of 437 patients mentioned that family deaths affect them and hinders them 
from collecting their medication, with the highest number affected from the deep rural (n=185; 54.4%) area.  
This is due to cultural beliefs where limited mobility is part of the signs of mourning, mostly affecting African 
females who are expected to gather in a room with the grieving mother of the deceased.  This probably accounts 
for over half of the patients (51.7%) missing between 2-4 appointments, the majority coming from the deep rural 
area.   
At the time of data collection for this study, all patients chosen for the study were issued with one month’s 
supply of medication. The pharmacy refill date given to the patient ensures that patients collect their next supply 
in time while the patients have not run out of medication.  Overall, 774 (75.9%) of patients in this study 
indicated that having sufficient stock at home allowed them not to collect their next supply.  Having stock at 
home by the time of the next refill appointment meant respondents were not taking their medication accordingly 
hence denoting non-adherence. 
A patient’s mental wellbeing can greatly affect adherence as feeling depressed may influence whether or not the 
patients end up taking their medication as required.
17 
 There was a significant association between patients who 
felt depressed and adherence (p=0.004) in this study.   
Half of the patients (n=517; 50.7%) in this study confirmed using traditional medicines, across all 3 areas of 
residence.  Although there was no statistical significance, the influence of traditional healers and religious 
leaders undermined the evidence-based medical community's efforts to initiate and retain patients on ART, with 
dire morbidity and mortality consequences.  Even after ART literacy classes, traditional beliefs outweighed faith 
in the healthcare system. The promise of a short-term, “curative” traditional remedy was more attractive than 
lifelong ART.  Furthermore, traditional healer services were perceived by patients to be more attentive and 




Family members' poor understanding of HIV and its transmission routes leads to stigmatization at home.
18
 Even 
though patients accept their HIV diagnosis they are still afraid to disclose to family members and sexual partners 
their HIV status for fear of being blamed for one's HIV infection or threat of expulsion from the home.
22
 In this 
study, there was a statistical significance between non-disclosure of status and adherence (p=0.008).  A larger 
proportion (62.4%) of patients who did not disclose their status was in the semi-urban area, which contributed to 
lower adherence levels seen in this area.  
In South Africa, AIDS sickness is coupled with eligibility for disability grants, and patients are entitled to a 
state-funded monthly income because of their illness-related incapacity to work. However, widespread 
unemployment has meant that disability grants are an important and at times the only source of income, even if 
patients are well enough to work. When disability grants are tied to AIDS-related indicators, such as CD4 counts 
or viral load, non-adherence may become an attractive option for patients who fear losing their grant if their 
CD4 count were to increase.
23
  There was an association found between the fear of loss of social grant and 
adherence to treatment (p=0.000).  Seventy percent (n=713) of patients feared losing their grants if their CD4 




In this study 396 respondents were employed, with 308 (77.8%) having reported not being granted leave or time 
off from work to collect their medication.  This impacts the patient’s ability to collect medication from health 
facility during the working hours of the health facility.  It was reported that costs incurred through lost wages to 
visit ART clinics were major obstacles to adherence, concurring with findings of a study done in Botswana.
15
   
Across all three regions, of the 623 (67%) patients on FDC in this study, a total of 413 respondents (66.3%) 
showed mistrust of the single FDC tablet.  There was a significant association between the mistrust of the new 
single (FDC) tablet and adherence level (p=0.023).  Hence education on the benefits of the FDC needs to be 
revised in order to allay their fears and mistrust. 
. 
The level of cleanliness of the environment as well as the perceived security of the respondents while within the 
facilities where they felt safe were reasons cited by patients that encouraged them to visit their clinics.  There 
was a significant association (p=0.000) between adherence and safety of the facility.  Most of patients (n=876; 
85.9%) felt safe in the health facility across all 3 areas which positively affected adherence.  This may somehow 
be associated with facility preference.  Facility preference was higher in the rural and deep rural areas thus 
positively influencing adherence to treatment in these areas. 
Studies previously done showed that the absence of a good patient and healthcare provider relationship and the 
poor attitude of the healthcare team at health facilities can be a significant barrier to adherence.
25
  In this study, 
staff attitude showed a significant association with adherence (p=000).  Almost 60% of patients received good 
staff attitudes from healthcare workers in the 3 different facilities, the highest being in the deep-rural area 
(n=242; 71.2%).  This concurs with the findings of this study which showed the highest percentage of adherent 
patients being in the deep-rural area.   
Food insecurity may affect the regularity of ART doses, as some patients have reported taking their medication 
only when they have food available. 
23
   This impacts on adherence because ARV medication cannot be taken on 
an empty stomach.  There was a significant association between food availability and area of residence 
(p=0.000). Patients in the semi-urban area reported having food frequently available at home (n=296; 87%), 
compared to those in the rural (n=100; 29.4%) and deep-rural (n=196; 57.6%), yet surprisingly had the least 
level of adherence to treatment (33.2%).    
A study done by Abdulrahman et al. 
26
 found that having daily reminders was one of the most important aids to 
taking medication on schedule. Taking medication on time positively affects adherence.   In this study, there 
was statistical significance found between use of reminder methods and adherence levels (p=0.002).  This 
affected patients equally in all the 3 different areas of residence.  
Limitations 
The largely rural location of the study may not be representative of the HIV-infected patient population at large.  
The study used a structured questionnaire which limited the possibility of in-depth understanding of the 
phenomenon under study since there were fixed responses to the questions that could not allow probing 
questions.  With a survey, the accuracy of responses to the questions by respondents may be affected by recall 
bias.  Adherence to long term therapy and its determinants is not a single incident but a continuous process over 
a period of time thus respondents may not be able to recall accurately their medication taking history.   
Conclusion and Recommendations 
More than half of the patients were adherent to treatment with the largest percentage residing in the deep-rural 
area, followed by rural then semi-urban area.   Most factors due to their geographical location contributed to 
patients being adherent or non-adherent, whilst at the same time there were other factors affecting adherence 
irrespective of where the patients’ geographical location was.   Factors that promoted adherence the most in the 
deep rural area were safe and clean facility, good staff attitudes and the use of reminder aids.  Factors that 
contributed towards poor adherence in the semi urban area included waiting time, not being granted leave from 
work, mistrust of the new single tablet, having no other caregiver at home, non-disclosure of status and feeling 
depressed.   
Though many studies have been done on adherence and many interventions implemented, adherence to 
treatment is still not optimal.  Therefore it is essential to monitor for adherence and to consistently measure 
patients’ understanding of the importance of adherence.  Educational interventions should be periodically 




medication. Identifying factors that contribute negatively to adherence due to patients’ geographical location is 
important to hasten the end of the epidemic of HIV/AIDS in South Africa.  
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3.1.1 The socio-demographic profile of the respondents 
Of the 1020 patients, 623 (61%) were females and 397 (39%) were males.  There was no association 
between gender and the level of adherence (p=0.817).  Some authors have reported that there was no 
correlation between gender and adherence which affirms the findings from this study.
19
 
The respondents were mostly in the youth category of 18-35years (n=580: 56.9%). Other respondents 
(n=439; 43.1%) were middle aged.   .This signified majority to be of young, sexually active and 
reproductive group.  In this study, there was no association found between adherence levels and age 
(p=0.996).  This finding agrees with a study done by Weidle et al.
20
   
The majority of respondents being females, and the prevalence of HIV in the 18-35 age group is 
consistent with the 2012 survey which found that HIV prevalence amongst South African women was 
nearly twice as high as men, 
21
 and that rates of new infections among women aged 15-24 were more 
than four times greater than that of men of the same age.
22
 
 Weidle et al 
20
 found that there was no association between marital status and adherence.  This agrees 
with findings of this study (p=0.601). 
In this study there was also no association found between the number of dependants of the 
respondents and adherence levels (p=0.997). 
The majority of patients (49%) in all the 3 different areas of the study had secondary level of 
education   .  There is no significant association between educational levels and adherence to 
treatment.  This concurs with the Weidle et al
20
 study which also found no association.   
In this study, none of the demographic variables/personal factors showed significant association to the 
adherence levels of the respondents.  This is consistent with studies done where socio-demographic 
factors generally did not predict adherence behaviour although some studies did find that male sex, 




These findings show that demographic factors such as age, gender, marital status, educational level, 
etc as one of the modifying factors that modify a person’s perception about a disease might not be 
predictors of or influence adherence to ART.
24
 
3.1.2 Level of adherence to ARV treatment and level of understanding of the importance of adherence 
23 
 
With respect to their understanding, although 80.9% of the respondents indicated that they understood 
the importance of adherence, an overall 58.5% were actually adherent to treatment, with the majority 
(89.4%) coming from the deep rural area (p=0.001) compared to the rural (52.9%) and semi urban 
(33.2%) areas.  This raises concerns as all patients included in this study had been on treatment for 
more than 2 years and provision of HIV/AIDS education and counselling to the patients is 
continuously done at every encounter with the healthcare providers at the healthcare facilities. The 
practice of being adherent by these patients appears to be neglected even though they are 
knowledgeable about the importance. A further survey determining what they actually understand 
about adherence and its importance should be carried out to devise appropriate interventions to help 
the patients obtain optimal adherence to ART. 
People taking antiretroviral medication and their supporters need to understand new and complex 
ideas around the medication itself, side effects, nutrition and positive living.  Treatment literacy aims 
to help individuals and communities understand why ARV treatment is needed, and what it can and 
cannot do.  Effective treatment literacy, developed by or with people living with HIV/AIDS and those 
taking ART, can lead to improved health outcomes, better adherence to drug regimens and higher 
uptake of health counselling and testing.   
3.1.3 Factors affecting adherence to ARV treatment 
3.1.3.1 Factors adversely affecting adherence 
In terms of the factors that affect adherence to ARV treatment, the time of travelling between home 
and the facilities was significantly associated with the area of residence (p=0.000).  A larger 
percentage of patients in the deep-rural and rural areas reported taking 2-3 hours to get to the facility 
having to travel a distance of 15 to 20km at a cost. In a study done in Botswana 
25
 it was reported that 
the cost incurred through transport to visit ART clinics was a major obstacle that had a negative 
impact on optimal adherence to ART.  This concurs with results found in this study where distance 
travelled to health facilities impacts on the transport costs thus adversely affecting adherence due to 
the burden of paying for transport to ART sites.   
The weather was significantly associated with the level of adherence to treatment (p=0.000).  A much 
higher proportion of the deep-rural area patients (73.8%) associated the weather with their ability to 
collect medication from the health facility.  Rainy weather makes it difficult to travel to ART sites 
from the deep rural area as rivers that are crossed on foot are sometimes full.  Great discomfort is also 
caused by sunny weather for patients who walk to these facilities. 
In terms of relating waiting time and adherence, there was a significant association noted between 
waiting time and adherence (p=0.000).   A total of 635 (62.3%) patients waited in the queue for 2 
hours and longer, with a significantly higher number of patients from the semi-urban (n=296; 87.1%) 
24 
 
area reported having waiting times of greater than 3 hours. A previous study found that patients who 
stayed in queues for a long time (4 hours or more) before being helped by service providers find it 




The death of a family member showed to have a statistical significance on level of adherence 
(p=0.000) and meeting their appointments.  A total of 437 patients mentioned that family deaths affect 
them and hinders them from collecting their medication, with the highest number affected from the 
deep rural (n=185; 54.4%) area.  This is due to cultural beliefs where limited mobility is part of the 
signs of mourning, mostly affecting African females who are expected to gather in a room with the 
grieving mother of the deceased.  This probably accounts for over half of the patients (51.7%) missing 
between 2-4 appointments, the majority coming from the deep rural area.   
Another contributory factor to missed appointments could be the availability or access to a caregiver. 
It was reported by about 25% (n=253) of patients that they are the only caregivers at home having to 
take care of their dependants.  This influences the patient’s availability to come to health facilities to 
collect their medication as the patients need to look for caretakers for their children on the day of 
collecting medication from ART sites. A greater proportion of these patients (n=124; 36.5%) were in 
the semi urban area where extended family system is not a common occurrence.   
At the time of data collection for this study, all patients chosen for the study were issued with one 
month’s supply of medication. The pharmacy refill date given to the patient ensures that patients 
collect their next supply in time while the patients have not run out of medication.  Overall, 774 
(75.9%) of patients in this study indicated that having sufficient stock at home allowed them not to 
collect their next supply.  Having stock at home by the time of the next refill appointment meant 
respondents were not taking their medication accordingly hence denoting non-adherence. 
A patient’s mental wellbeing can greatly affect adherence as feeling depressed may influence whether 
or not the patients end up taking their medication as required.
27 
 There was a significant association 
between patients who felt depressed and adherence (p=0.004) in this study.   
Half of the patients (n=517; 50.7%) in this study confirmed using traditional medicines, across all 3 
areas of residence.  Although there was no statistical significance, the influence of traditional healers 
and religious leaders undermined the evidence-based medical community's efforts to initiate and 
retain patients on ART, with dire morbidity and mortality consequences.  Even after ART literacy 
classes, traditional beliefs outweighed faith in the healthcare system. The promise of a short-term, 
“curative” traditional remedy was more attractive than lifelong ART.  Furthermore, traditional healer 
services were perceived by patients to be more attentive and individualized than clinic care, creating 





Alcohol as a factor influencing adherence is cited in many studies 
29, 30
.  In this study there was a 
statistical significance between alcohol use and adherence to medication (p=0.000).  The reported use 
of alcohol was higher in the deep-rural area (n=318; 93.5%) than in the other areas, which was 
consistent with findings of a previous study.
31
  
Although 25.4% of respondents in this study reported substance abuse having similarly affected 
respondents in all 3 areas, there was no association to  adherence (p=0.764).    
Family members' poor understanding of HIV and its transmission routes leads to stigmatization at 
home.
28
 Even though patients accept their HIV diagnosis they are still afraid to disclose to family 
members and sexual partners their HIV status for fear of being blamed for one's HIV infection or 
threat of expulsion from the home.
32
 In this study, there was a statistical significance between non-
disclosure of status and adherence (p=0.008).  A larger proportion (62.4%) of patients who did not 
disclose their status was in the semi-urban area, which contributed to lower adherence levels seen in 
this area.  
In South Africa, AIDS sickness is coupled with eligibility for disability grants, and patients are 
entitled to a state-funded monthly income because of their illness-related incapacity to work. 
However, widespread unemployment has meant that disability grants are an important and at times the 
only source of income, even if patients are well enough to work. When disability grants are tied to 
AIDS-related indicators, such as CD4 counts or viral load, non-adherence may become an attractive 
option for patients who fear losing their grant if their CD4 count were to increase.
33
  There was an 
association found between the fear of loss of social grant and adherence to treatment (p=0.000).  
Seventy percent (n=713) of patients feared losing their grants if their CD4 cell count improved, with 
the greatest fear in the deep rural area (88.5%). 
In this study 396 respondents were employed, with 308 (77.8%) having reported not being granted 
leave or time off from work to collect their medication.  This impacts the patient’s ability to collect 
medication from health facility during the working hours of the health facility.  It was reported that 
costs incurred through lost wages to visit ART clinics were major obstacles to adherence, concurring 
with findings of a study done in Botswana.
25 
  
Across all three regions, of the 623 (67%) patients on FDC in this study, a total of 413 respondents 
(66.3%) showed mistrust of the single FDC tablet.  There was a significant association between the 
mistrust of the new single (FDC) tablet and adherence level (p=0.023).  Hence education on the 
benefits of the FDC needs to be revised in order to allay their fears and mistrust. 
In this study, pill burden was classified as those patients taking 4 or more tablets at a time.    Pill 
burden affected 66.1% of all patients, the highest being in the semi-urban area (68.2%), although 
having shown  no association between pill burden and level of adherence (p=0.514).   
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Changing medication in ART would be indicated as a result of severe side effects, drug interactions as 
a result of co-morbidity or that medications are failing to control the HIV virus.  Medication failure as 
a reason for change is least in this study as only 6% (n=62) of patients in this study are on a second 
line regimen.  There were no reported switches of medication from one first line regimen to the other, 
for patients who are still using single agents and are not on FDC.   
Although no significant association was found between side effects and adherence (0.995), side-
effects were raised by 67.9% (n=693) of patients as one of the reasons for non-adherence to treatment, 
with 36% having chronic rash, 22.2% with weight issues (weight gain or weight loss), 9.2% with 
lipodystrophy and 1% with gynaecomastia.   
The time of taking medication (i.e. morning, noon, afternoon, evening, night, morning and nighty) has 
no statistical significance (p=0.964).  Those patients who are on fixed dose combination (FDC) 
medication preferred to take their medication at noon (n=351; 34.4%) and those on single agents 
(n=275; 27%) took their medication in the morning and night.   Only 18.8% of patients taking single 
agent medication missed one of the daily doses of medication.  Of these patients, 25.9% are from the 
semi-urban area.  There was statistical significance between missed doses and adherence (p=0.000). 
Feeling better was identified as a barrier to medication adherence in some patients. 
34   
This concurs 
with this study where over half of the patients (51.3%) did not sometimes see the need to take their 
medication due to feeling better.  This generally affected patients in all 3 different areas of residence. 
3.1.3.2 Factors promoting adherence 
The level of cleanliness of the environment as well as the perceived security of the respondents while 
within the facilities where they felt safe were reasons cited by patients that encouraged them to visit 
their clinics.  There was a significant association (p=0.000) between adherence and safety of the 
facility.  Most of patients (n=876; 85.9%) felt safe in the health facility across all 3 areas which 
positively affected adherence.  This may somehow be associated with facility preference.  Facility 
preference was higher in the rural and deep rural areas thus positively influencing adherence to 
treatment in these areas. 
Studies previously done showed that the absence of a good patient and healthcare provider 
relationship and the poor attitude of the healthcare team at health facilities can be a significant barrier 
to adherence.
35
  In this study, staff attitude showed a significant association with adherence (p=000).  
Almost 60% of patients received good staff attitudes from healthcare workers in the 3 different 
facilities, the highest being in the deep-rural area (n=242; 71.2%).  This concurs with the findings of 
this study which showed the highest percentage of adherent patients being in the deep-rural area.   
Food insecurity may affect the regularity of ART doses, as some patients have reported taking their 
medication only when they have food available. 
33
 This impacts on adherence because ARV 
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medication cannot be taken on an empty stomach.  There was a significant association between food 
availability and area of residence (p=0.000). Patients in the semi-urban area reported having food 
frequently available at home (n=296; 87%), compared to those in the rural (n=100; 29.4%) and deep-
rural (n=196; 57.6%), yet surprisingly had the least level of adherence to treatment (33.2%).    
A study done by Abdulrahman et al, 
36
 found that having daily reminders was one of the most 
important aids to taking medication on schedule. Taking medication on time positively affects 
adherence.   In this study, there was statistical significance found between use of reminder methods 
and adherence levels (p=0.002).  This affected patients equally in all the 3 different areas of residence.  
3.2 Limitations 
The study used a structured questionnaire which limited the possibility of in-depth understanding of 
the phenomenon under study since there were fixed responses to the questions that could not allow 
probing questions.  With a survey, the accuracy of responses to the questions by respondents may be 
affected by recall bias.  Adherence to long term therapy and its determinants is not a single incident 
but a continuous process over a period of time thus respondents may not be able to recall accurately 
their medication taking history.   
3.3 Conclusion and Recommendations 
More than half of the patients were adherent to treatment with the largest percentage residing in the 
deep-rural area, followed by rural then semi-urban area.   Most factors due to their geographical 
location contributed to patients being adherent or non-adherent, whilst at the same time there were 
other factors affecting adherence irrespective of where the patients’ geographical location was.   
Factors that promoted adherence the most in the deep rural area were safe and clean facility, good 
staff attitudes and the use of reminder aids.  Factors that contributed towards poor adherence in the 
semi urban area included waiting time, not being granted leave from work, mistrust of the new single 
tablet, having no other caregiver at home, non-disclosure of status and feeling depressed.   
Though many studies have been done on adherence and many interventions implemented, adherence 
to treatment is still not optimal.  Therefore it is essential to monitor for adherence and to consistently 
measure patients’ understanding of the importance of adherence.  Educational interventions should be 
periodically carried out every 6 months in order to reinforce the importance of being adherent and 
preventing resistance to medication. Identifying factors that contribute negatively to adherence due to 
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Appendix 1:  Information Sheet and Consent form  
UKZN BIOMEDICAL RESEARCH ETHICS COMMITTEE 
 
APPLICATION FOR ETHICS APPROVAL  
For research with human participants (Biomedical) 
 
 
INFORMED CONSENT FORM FOR PARTICIPANTS 
 
 
Information Sheet and Consent to Participate in Research 
 
Date:_________________________   
 
 
Hello, my name is Phumelele Mthethwa from the University of Kwazulu-Natal, School of 
Health Sciences, Discipline of Pharmaceutical Sciences.  I am a researcher working under 
the University of Kwazulu-Natal. I can be contacted on 039 688 3046 / 0833148515 or 
emailed at phumelele.mthethwa@kznhealth.gov.za / phumelelen@yahoo.com. I am 
working on a research study entitled “Measure of adherence to antiretroviral treatment 
amongst HIV positive patients attending antiretroviral clinics in selected rural, deep 
rural and semi-urban areas of KwaZulu-Natal” 
 
You are being invited to consider participating in a study that involves research.   Before 
agreeing to participate, it is important that you read and understand the purpose of the 
study, the study procedures, benefits, risks and your right to withdraw yourself from the 
study at any time.  You should not agree to take part unless you are satisfied about all the 
procedures involved.  If you decide to take part in this study, you will be asked to sign 
and date this Informed Consent Form to confirm that you understand the study.  You will 
be given a copy to keep. 
 
THE AIM AND PURPOSE OF THE STUDY  
The aim of the study is to find out what causes people who are on antiretroviral 
treatment not to collect and take their medication as instructed by their doctor/ 
pharmacist/ nurse at the hospital/ clinic they attend every month.  The information that 
will be collected during the study will be used by the Department of Health to help in 
finding new systems and methods in improving adherence to treatment. 
 
LENGTH OF THE STUDY AND NUMBER OF PARTICIPANTS 
The study is expected to enroll a total of 1020 participants, with 340 patients being from 
a semi-urban hospital, 340 from a rural clinic or community health centre or hospital and 
340 from a very rural clinic within Ugu District. 





This facility has been selected to participate in the study a random.  If you agree to 
participate in the study, the researcher will look at your medical records and ask you 
questions about you and how you take your treatment.  The researcher will also ask you 
questions to find out the reasons for not taking your treatment in times where it was not 
taken.  Answering these questions should take 15-20minutes of your time. 
 
The study is funded by the School of Health Sciences of the University of KwaZulu-Natal. 
 
CONFIDENTIALITY 
We will not record your name or any other identifier so all information collected during 
the interview will be kept confidential.  Results of this study will not be presented in a 
way that individual participants can be identified, however, results will be presented such 
that if there are differences in factors affecting adherence due to the location of the 
facility, it can be identified with that facility. 
 
Your medical records of collection of treatment for the past year that will be reviewed to 
ascertain adherence to treatment will be kept confidential at all times.  The interview 
that will be conducted with you to find out your reasons (if any) for not collecting and 
taking your medication will be done in a private room with only the researcher and you 
to ensure confidentially of what is discussed. 
 
Although every precaution will be taken to ensure confidentiality, absolute 
confidentiality cannot be guaranteed. 
 
BENEFITS 
There are no direct benefits to you today.  However, the information collected during this 
study will be used by the Government, particularly the Department of Health, to help 
improve in finding new systems and methods in improving adherence to treatment. 
You will not receive any compensation for participating in this study. 
RISKS / DISCOMFORTS 
This study has few risks for you to participate but will require some of your time.  If you 
choose to participate in this study, you may refuse any questions that you do not want to 
answer. 
If you are uncomfortable you may withdraw from the study without any penalties.  
However, if answering the questionnaire is going to cause any psychological discomfort, 
please notify the data collector immediately who will escort you to a health professional 
for further management. 
 
ETHICS APPROVAL 
This study has been ethically reviewed and approved by the UKZN Biomedical research 
Ethics Committee (approval number_____).  A copy may be obtained from me should 
you wish to review it. 
 





WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS? 
In the event of any problems or concerns/questions you may contact the researcher 
(Phumelele Mthethwa, KZN Department of Health, Manager:  Pharmaceutical Services, 
Ugu Health District Office, P/Bag x 735, Port Shepstone 4240, Tel:  039 688 3046, Cell:  
0833148515, email:  phumelele.mthethwa@kznhealth.gov.za / phumelelen@yahoo.com 
) or the UKZN Biomedical Research Ethics Committee, contact details as follows:  
 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
             
YOUR RIGHTS AS A PARTICIPANT  
Your participation in this research is voluntary.  You may withdraw your participation in 
the study at any time, without stating any reason.  In the event of refusal/withdrawal of 
participation you will not incur penalty or loss of treatment or other benefit to which you 
are normally entitled.  
 
You may come to the researcher physically or contact the researcher telephonically or by 
email to withdraw from the study, stating your name and the health facility that you 
were interviewed from.   
 




All new findings or any additional information that becomes available during the study, 
which may affect your willingness to continue in the study, will be made known to you as 






I, ________________________________________________, have been informed about 
the study entitled “Measure of adherence to antiretroviral treatment amongst HIV 
positive patients attending antiretroviral clinics in selected rural, deep rural and semi-
urban areas of KwaZulu-Natal”  by Phumelele Mthethwa, the  researcher. 
 








I have been given an opportunity to ask questions about the study and have had answers 
to my satisfaction. 
 
I declare that my participation in this study is entirely voluntary and that I may withdraw 
at any time without affecting any treatment or care that I would usually be entitled to. 
 
If I have any further questions/concerns or queries related to the study I understand that 
I may contact the researcher (Phumelele Mthethwa, KZN Department of Health, 
Manager:  Pharmaceutical Services, Ugu Health District Office, P/Bag x 735, Port 
Shepstone 4240, Tel:  039 688 3046, Cell:  0833148515, email:  
phumelele.mthethwa@kznhealth.gov.za / phumelelen@yahoo.com). 
 
If I have any questions or concerns about my rights as a study participant, or if I am 
concerned about an aspect of the study or the researchers then I may contact: 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 




____________________      ____________________ 
Signature of Participant                            Date 
 
 
____________________   _____________________ 
Signature of Witness                                Date 
(Where applicable)      
 
 
____________________   _____________________ 






Appendix 2:  Questionnaire
QUESTIONNAIRE  Page 1 of 1 
 
  PARTICIPANT’S DETAILS 
PATIENT CODE:    
NAME OF FACILITY: AGE: GENDER:  
M F 
 








OCCUPATION: CURRENT REGIMEN: 
EDUCATIONAL STATUS/LEVEL: 
Never attended 1⁰ 2⁰ 3⁰ 
 
MODE OF TRANSPORT: 
Private Public Lift Club Foot Other: 
 
DATE OF LAST CLINIC VISIT: TODAY’S DATE: 
NO. OF MISSED VISITS/APPOINTMENTS: DURATION OF PERIOD ON TREATMENT:   







FACTORS AFFECTING ADHERENCE: 




2. Traditional medicine use 
Never Monthly Weekly Daily 
 
3. Alcohol use   
Never Monthly Weekly Daily 
 
4. I wait for public transport to / from the clinic/CHC/hospital for up to 
0-1hr 1-2hrs 2-3hrs >3hrs 
 
5. The clinic/CHC/hospital is______from my house  
<5km 5-10km 10-15km 15-20km >20km 
 






7. Safety of place of collection  
Good Bad 
 
8. I like the facility 
Yes No 
 
9. Staff attitude & service at the facility 
Good Bad 
 
10. Waiting time at the facility 
0-1hr 1-2hrs 2-3hrs >3hrs 
 
11. Death in family / neighbourhood   
Yes No 
 
12. No other caregiver at home 
Yes No 
 
13. I had sufficient stock at home 
Yes No 
 
14. Unable to attain leave from work during hours of operation of facility 
Yes No 
 
15. I was feeling better so saw no need to collect medication 
Yes No 
 
16. Taking the medication always makes me feel depressed 
Yes No 
 
17. Reminder method (alarm/ Rx buddy/ Family/ Spouse/ Child) not effective 
Yes No 
 
18. At what time of the day do you take your medication 
morning noon afternoon evening night morning & 
evening 
 







20. I have too many pills to take  






21. I smoke /use drugs e.g wonger  
Yes No 
 
22. When I came to the facility last time/month there was no stock and could not come back 
Yes No 
 
23. My regimen changed and the new regimen makes me feel sick all the time 
Yes No 
 
24. Taking the medication has caused general physiological side effects  
Chronic rash Weight gain/loss lipodystrophy gynaecomastia other 
 
25. Fear of losing social grant when CD4 count measurement rises 
Yes No 
 
26. I have not disclosed my status to family due to stigma of HIV in the family & fear of discrimination 
Yes No 
 
27. I sometimes only remember to take my first dose of medication in the morning and forget to take my  second dose of 
medication in the evening (OR vise versa) 
Yes No 
 
28. I have been taking my medication twice a day all along and I don’t trust the new pill (one pill) taken once a day (FDC).  So I 
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